By Ben Glickman


Shares of Caribou Biosciences rose after the company's lymphoma trial design was approved by the Food and Drug Administration.

The stock was up 4.1% to $5.88 in after-hours trading following a 1.9% drop at Tuesday's close. Shares are down 10% this year.

The Berkeley, Calif.-based gene-editing pharmaceutical company said it had received feedback from the FDA on its Phase 3 trial for CB-010, a treatment for large B cell lymphoma.

The company plans to initiate its Phase 3 trial by the end of 2024.

The trial design includes platinum-based immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation.

Chief Executive Rachel Haurwitz said the FDA feedback was "an important step in advancing our lead therapy."


Write to Ben Glickman at ben.glickman@wsj.com


(END) Dow Jones Newswires

12-12-23 1811ET